Subjective Well Being of Patients Receiving Atypical Antipsychotics as Monotherapy or Cotherapy With Mood Stabilizers

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00691353

Acronym

DIDAXI

Enrollment

540

Registered

2008-06-05

Start date

2008-04-30

Completion date

2008-07-31

Last updated

2008-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder

Keywords

Bipolar Disorder, antipsychotics, social functioning, mood stabilizers, Bipolar Disorder Type I, atypical antipsychotics, monotherapy, cotherapy

Brief summary

Cross - Sectional study requiring one visit at the investigators office for the data collection. * Target Group: Patients that suffer from Bipolar Disorder Type 1. * YMRS - HAMILTON and GAF scales are going to be used to assess the clinical outcome. The findings are going to be based on the different scores reported by Specialists (before the patients started to use as a therapy atypical antipsychotics / at the time that the visit actually takes place for the cause of the study.) We predefine the time period that the patient should be using atypical antipsychotics at minimum (2 months). * The first 9 consecutive patients that visit the Specialist and meet the entry criteria and signs the ICF will be recruited in the study.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients that are diagnosed with Bipolar Disorder Type 1 according to diagnostic criteria DSM - IV * Patients that have started therapy with atypical antipsychotics as monotherapy or cotherapy with mood stabilizers the last three months, but have completed 2 full months of therapy. * Patients with anxiety disorder can be recruited in the study unless it is dominant.

Exclusion criteria

* Patients that use antidepressant medication * Patients who were treated with depot antipsychotic in the last quarter before their enrollment in the study. * Patients who are addicts of toxic substances. * Patients who suffer from other serious diseases.

Design outcomes

Primary

Measure	Time frame
Difference in the scores reported in YMRS and Hamilton - D scales from baseline(start of therapy)	Assessment of the progress of disease 2 to 4 months after the initiation of the therapy(baseline)
Assessment of functioning - Relative score reported in GAF scale	2 - 4 months after the initiation of the therapy. No baseline comparison

Secondary

Measure	Time frame
To depict sociodemographic characteristics and comorbidities.	Reported at the site visit

Countries

Greece

Outcome results